An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver

An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver

Hepatitis C is a common cause of end-stage liver disease, and the main indication for liver transplantation in Latin America. Treatment of hepatitis C infected patients improves important long-term outcomes as mortality. Sustained viral response is reached in near 50% of patients with the previous m...

Full description

Bibliographic Details
Main Authors: Norberto C. Chávez-Tapia, Ezequiel Ridruejo, Angelo Alves de Mattos, Fernando Bessone, Jorge Daruich, Juan F. Sánchez-Ávila, Hugo Cheinquer, Rodrigo Zapata, Misael Uribe, Francisco Bosques-Padilla, Adrián Gadano, Alejandro Soza, Milagros Dávalos-Moscol, Claudio Marroni, Linda Muñoz-Espinoza, Graciela Castro-Narro, Raymundo Paraná, Nahum Méndez-Sánchez, MD, MSc, PhD, FACG, AGAF
Format: Article
Language:English
Published: Elsevier 2013-03-01
Series:Annals of Hepatology
Subjects:
Consensus
Therapeutics
Boceprevir
Liver diseases
Chronic hepatitis C
Telaprevir
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119314048
Description
Summary:Hepatitis C is a common cause of end-stage liver disease, and the main indication for liver transplantation in Latin America. Treatment of hepatitis C infected patients improves important long-term outcomes as mortality. Sustained viral response is reached in near 50% of patients with the previous management based in pegylated interferon and ribavirin. Recently new drugs were available increasing sustained viral response significantly, changing the standard of care to triple therapy. This guidelines provides a framework for practitioner in Latin America, to the management of patients with hepatitis C chronic infection.
ISSN:1665-2681

Similar Items